- Home
- BEEM vs SCLX Comparison
BEEM vs SCLX Comparison
Compare BEEM & SCLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BEEM
- SCLX
- Stock Information
- Founded
- BEEM 2006
- SCLX 2011
- Country
- BEEM United States
- SCLX United States
- Employees
- BEEM N/A
- SCLX N/A
- Industry
- BEEM Semiconductors
- SCLX Biotechnology: Pharmaceutical Preparations
- Sector
- BEEM Technology
- SCLX Health Care
- Exchange
- BEEM Nasdaq
- SCLX Nasdaq
- Market Cap
- BEEM 35.5M
- SCLX 35.7M
- IPO Year
- BEEM N/A
- SCLX N/A
- Fundamental
- Price
- BEEM $2.52
- SCLX $18.87
- Analyst Decision
- BEEM Strong Buy
- SCLX Strong Buy
- Analyst Count
- BEEM 4
- SCLX 3
- Target Price
- BEEM $5.33
- SCLX $367.50
- AVG Volume (30 Days)
- BEEM 200.0K
- SCLX 324.6K
- Earning Date
- BEEM 08-14-2025
- SCLX 08-13-2025
- Dividend Yield
- BEEM N/A
- SCLX N/A
- EPS Growth
- BEEM N/A
- SCLX N/A
- EPS
- BEEM N/A
- SCLX N/A
- Revenue
- BEEM $33,362,000.00
- SCLX $44,236,000.00
- Revenue This Year
- BEEM N/A
- SCLX $89.26
- Revenue Next Year
- BEEM $38.51
- SCLX $203.95
- P/E Ratio
- BEEM N/A
- SCLX N/A
- Revenue Growth
- BEEM N/A
- SCLX N/A
- 52 Week Low
- BEEM $1.33
- SCLX $3.60
- 52 Week High
- BEEM $5.90
- SCLX $45.15
- Technical
- Relative Strength Index (RSI)
- BEEM 56.64
- SCLX 63.34
- Support Level
- BEEM $2.31
- SCLX $15.61
- Resistance Level
- BEEM $2.77
- SCLX $22.01
- Average True Range (ATR)
- BEEM 0.21
- SCLX 2.21
- MACD
- BEEM -0.01
- SCLX -0.14
- Stochastic Oscillator
- BEEM 62.69
- SCLX 62.35
About BEEM Beam Global
Beam Global produces sustainable technology for electric vehicle (EV) charging, outdoor media, and energy security, without the construction, disruption, and costs of grid-tied solutions. Its products are founded upon its patented EV ARC and Solar Treelines and include BeamTrak patented solar tracking, and ARC Technology energy storage, along with EV charging, outdoor media, and disaster preparedness packages. From start to finish, the company develops, patents, designs, engineers, and manufactures renewably energized products that help the environment, empower communities, and keep people moving.
About SCLX Scilex Holding Company
Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for relieving pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.